FAT10 level in human gastric cancer and its relation with mutant p53 level, lymph node metastasis and TNM staging

Table 1 Primers used in this study

Designation	Sequences	PCR products (bp)
β-actin
Upstream primer	5’-TCACCCACACCGTGCCCATCTACGA-3’	295
Downstream primer	5’-CAGCGGAACCGCTCATTGCCAACGG-3’
FAT10
Upstream primer	5’-AATGCTTCCTGCCTCTGTGT-3’	478
Downstream primer	5’-GCCGTAATCTGCCATCATCT-3’
Mutant p53
Upstream primer	5’-CCTATGGAAACTACTTCCTGAAAACAA-3’	492
Downstream primer	5’-ACAGCATCAAATCATCCATTGC-3’

Table 2 FAT10 and mutant p53 protein expression in gastric cancer tissue and its adjacent tissue and normal tissue n (%)

Tissue	FAT10		Mutant p53
	Negative	Positive	Negative	Positive
Gastric tissue	30	32 (51.61)	34	28 (45.16)
Tumor-adjacent tissue	54	8 (12.90)	53	9 (14.51)
Normal gastric tissue	58	4 (6.45)	56	6 (9.68)

Table 3 Relation between FAT10 expression and clinicopathologic factors for gastric cancer

Clinic pathologic factors	Samples	FAT10 positive samples (%)	χ2	P
Age (yr)
< 50	19	7 (36.84)	2.39	> 0.05
≥ 50	43	25 (58.14)
Gender
Male	38	19 (50.00)	0.1	> 0.05
Female	24	13 (54.16)
Tumor size (cm)
< 5	33	16 (48.48)	0.28	> 0.05
≥ 5	29	16 (55.17)
Location
Antrum	31	15 (48.39)	2.81	> 0.05
Angle	5	2 (40.00)
Body	14	9 (64.29)
Fundus	4	3 (75.00)
Cardia	8	3 (37.50)
Progression degree
Early stage	11	6 (54.54)	0.05	> 0.05
Progressive stage	51	26 (50.98)
Differentiation degree
High, middle	15	7 (46.67)	0.19	> 0.05
Low, none	47	25 (53.19)
Lymph metastasis
Positive	39	25 (64.10)	6.57	< 0.05
Negative	23	7 (30.43)
Distant metastasis
Positive	15	11 (73.33)	3.74	> 0.05
Negative	47	21 (44.68)
TNM Staging
I + II	21	7 (33.33)	4.25	< 0.05
III + IV	41	25 (60.98)

Table 4 Relation between FAT10-mRNA level and clinicopathological factors for gastric cancer

Clinicopathological factors	Samples (n)	Positive samples	Strap gray value (mean ± SD)	t-value	P
Age (yr)
< 50	19	10	0.583 ± 0.036	1.12	> 0.05
≥ 50	43	26	0.611 ± 0.026
Sex
Male	38	21	0.622 ± 0.013	1.36	> 0.05
Female	24	15	0.574 ± 0.024
Tumor size (cm)
< 5 cm	33	19	0.594 ± 0.022	0.65	> 0.05
≥ 5 cm	29	17	0.590 ± 0.018
Location
Tantrum	31	17	0.537 ± 0.019	1.54	> 0.05
Angle	5	3	0.672 ± 0.037
Body	14	9	0.594 ± 0.021
Fundus	4	4	0.611 ± 0.025
Cardia	8	3	0.529 ± 0.032
Progression degree
Early	11	8	0.623 ± 0.023	1.15	> 0.05
Advanced	51	28	0.597 ± 0.020
Differentiation degree
Well-middle	15	9	0.564 ± 0.031	1.39	> 0.05
Low-non	47	27	0.595 ± 0.019
Lymph node metastasis
Positive	39	27	0.656 ± 0.016	3.37	< 0.01
Negative	23	9	0.531 ± 0.026
Distant metastasis
Positive	15	12	0.623 ± 0.033	1.74	> 0.05
Negative	47	24	0.598 ± 0.017
TNM stage
I + II	21	8	0.667 ± 0.023	2.25	< 0.05
III + IV	41	28	0.558 ± 0.015

Table 5 Correlation between FAT10 and mutant p53 expressions in gastric cancer tissue

p53	Samples	FAT10 expression
		Positive	Negative
Positive	28	23	5
Negative	34	9	25
Total	62	32	30

Table 6 Cox regression model analysis results of the prognostic factors for gastric cancer

Harzard factors	B	S χ	Wald	υ	Sig.	Exp (B)
Age	0.134	0.144	0.853	1	0.533	1.012
Tumor size	0.243	0.246	0.804	1	0.368	0.763
Location	0.072	0.055	1.846	1	0.173	0.954
Progression	0.144	0.267	0.26	1	0.615	1.148
Differentiation degree	0.544	0.23	2.613	1	0.118	1.223
Lymph node metastasis	0.734	0.384	4.985	1	0.027	1.886
Distant metastasis	0.764	0.326	6.785	1	0.001	1.806
TNM stage	0.698	0.285	7.205	1	0.007	1.745
FAT10 protein	0.661	0.228	8.448	1	0.004	1.516
FAT10 mRNA	0.793	0.245	7.658	1	0.003	1.854
p53 protein	0.669	0.239	6.479	1	0.006	1.611
p53 mRNA	0.758	0.346	6.857	1	0.004	1.521